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In Response to Healy 
JOHN M. KANE 
It is always a challenge to comment on 
an article which attempts to draw together 
topics as complex and diverse as: the role 
of psychodynamic therapy in war time 
soldiers; the role of the asylum in western 
history; the Harrison Narcotics act of 1914; 
the Food Drugs and Cosmetics Act; the role 
of contraception in social change; the 
Enlightenment; the efficacy and image of 
ECT in medicine and the lay public; the 
evolution of our understanding of tardive 
dyskinesia; the role of clinical trials in 
medicine and drug development; the "poli-
tics" of psychopharmacology; publication 
bias; changes in popular psychology over 
the last 50 years; drug dependence; de-
institutionalization; "corporate psychiatry"; 
"Big Science"; the development of receptor 
assay technology; the role of psychological 
testing in establishing societal and medical 
"norms"; the differences between managing 
the risk factors for a disease and the disease 
itself; pharmaceutical and other corporate 
marketing; the relationship between the 
pharmaceutical industry and academia; the 
justifications for pediatric psychopharma-
cology; the epidemiology of eating disor-
ders; - to mention only some. 
In my experience, when one attempts to 
draw together so many disparate and com-
plex issues in a ten-page paper, it is likely 
that some lapses in rigor will occur. In 
some such situations, what might appear 
initially and superficially to be "scholarly," 
rapidly becomes what would more appro-
priately be labeled as "intellectually irre-
sponsible". So in the midst of all of this, 
we find statements such as "clinical trials 
in psychiatry, however, have never shown 
that anything worked". I pray that it is not 
only cognitive dissonance that leads me 
reject such a statement. 
Another example, "when the new (am 
sychotic) drugs came, starting with clozapi 
they came not because they were better d 
the older drugs, but rather because clozap 
didn't cause tardive dyskinesia". As sor 
one who was intimately involved in 
clinical development and FDA approval 
clozapine, I would point out that clozapii 
low propensity to cause tardive dyskini 
was not a major factor in leading to 
approval (and has not been a major is 
in the "marketing" Gf clozapine either 
I cite these as but examples. The aut 
certainly touches on areas where clc 
scrutiny and further scientific debate 
critical. One could certainly complim 
the author on his broad range of interi 
and the ambitiousness of his review; h( 
ever, it ultimately fails as a vehicle 
informing the reader or enhancing app 
priate debate. 
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